ID30262A - Ligan reseptor melanokortin - Google Patents

Ligan reseptor melanokortin

Info

Publication number
ID30262A
ID30262A IDW00200102111A ID20012111A ID30262A ID 30262 A ID30262 A ID 30262A ID W00200102111 A IDW00200102111 A ID W00200102111A ID 20012111 A ID20012111 A ID 20012111A ID 30262 A ID30262 A ID 30262A
Authority
ID
Indonesia
Prior art keywords
melanokortin
ligan
receptor
ligan receptor
Prior art date
Application number
IDW00200102111A
Other languages
English (en)
Indonesian (id)
Inventor
Adam W Mazur
Feng Wang
Russell J Sheldon
Frank H Ebetino
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of ID30262A publication Critical patent/ID30262A/id

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • C07K14/685—Alpha-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Pregnancy & Childbirth (AREA)
  • Communicable Diseases (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
IDW00200102111A 1999-03-29 2000-03-21 Ligan reseptor melanokortin ID30262A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12667399P 1999-03-29 1999-03-29

Publications (1)

Publication Number Publication Date
ID30262A true ID30262A (id) 2001-11-15

Family

ID=22426131

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW00200102111A ID30262A (id) 1999-03-29 2000-03-21 Ligan reseptor melanokortin

Country Status (34)

Country Link
US (2) US6613874B1 (zh)
EP (1) EP1165613B1 (zh)
JP (1) JP2002542159A (zh)
KR (2) KR100558131B1 (zh)
CN (1) CN1249086C (zh)
AR (1) AR023201A1 (zh)
AT (1) ATE393783T1 (zh)
AU (1) AU763510B2 (zh)
BR (1) BR0009497A (zh)
CA (1) CA2368431C (zh)
CO (1) CO5170531A1 (zh)
CZ (1) CZ20013407A3 (zh)
DE (1) DE60038734T2 (zh)
DK (1) DK1165613T3 (zh)
ES (1) ES2304345T3 (zh)
HK (1) HK1044954B (zh)
HU (1) HUP0202203A3 (zh)
ID (1) ID30262A (zh)
IL (1) IL145406A0 (zh)
MA (1) MA25403A1 (zh)
MX (1) MXPA01009881A (zh)
MY (1) MY126585A (zh)
NO (1) NO20014568L (zh)
NZ (1) NZ514141A (zh)
PE (1) PE20001641A1 (zh)
PL (1) PL350095A1 (zh)
PT (1) PT1165613E (zh)
RU (1) RU2213098C2 (zh)
SA (1) SA00210192B1 (zh)
SK (1) SK13082001A3 (zh)
TR (1) TR200102765T2 (zh)
TW (1) TWI250990B (zh)
WO (1) WO2000058361A1 (zh)
ZA (1) ZA200107411B (zh)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002064091A2 (en) 2001-02-13 2002-08-22 Palatin Technologies, Inc. Melanocortin metallopeptides for treatment of sexual dysfunction
US7192713B1 (en) 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
EP1187614A4 (en) 1999-06-04 2005-06-22 Merck & Co Inc SUBSTITUTED PIPERIDINES THAN MELANOCORTIN-4 RECEPTOR AGONISTS
US7235625B2 (en) 1999-06-29 2007-06-26 Palatin Technologies, Inc. Multiple agent therapy for sexual dysfunction
EP1251865A1 (en) 2000-01-18 2002-10-30 Merck & Co., Inc. Cyclic peptides as potent and selective melanocortin-4 receptor antagonists
PT1315750E (pt) 2000-08-30 2007-05-31 Hoffmann La Roche Péptidos cíclicos com actividade agonista para o receptor 4 de melanocortina
JP2004509974A (ja) * 2000-09-27 2004-04-02 ザ　プロクター　アンド　ギャンブル　カンパニー メラノコルチンの受容体リガンド
US7345144B2 (en) * 2001-07-11 2008-03-18 Palatin Technologies, Inc. Cyclic peptides for treatment of cachexia
US7342089B2 (en) * 2001-07-11 2008-03-11 Palatin Technologies, Inc. Cyclic peptides for treatment for cachexia
JP2004534851A (ja) 2001-07-11 2004-11-18 パラチン テクノロジーズ インク． メラノコルチン受容体に特異的な線状および環状ペプチド
US20030195187A1 (en) * 2002-02-04 2003-10-16 Chiron Corporation Guanidino compounds
US7034004B2 (en) * 2002-05-07 2006-04-25 University Of Florida Peptides and methods for the control of obesity
US7323462B2 (en) 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
WO2005000339A2 (en) * 2003-06-19 2005-01-06 Eli Lilly And Company Melanocortin receptor 4(mc4) agonists and their uses
WO2005000338A1 (en) * 2003-06-19 2005-01-06 Eli Lilly And Company Uses of melanocortin-3 receptor (mc3r) agonist peptides
RU2381233C2 (ru) * 2003-09-30 2010-02-10 Ново Нордиск А/С Агонисты рецептора меланокортина
EP1680443B9 (en) * 2003-11-05 2014-09-03 Dana-Farber Cancer Institute, Inc. Stabilized alpha helical peptides and uses thereof
AU2015201062B2 (en) * 2003-11-05 2017-03-09 Dana-Farber Cancer Institute, Inc. Stabilized alpha helical peptides and uses thereof
EP2368579A1 (en) 2004-01-21 2011-09-28 Novo Nordisk Health Care AG Transglutaminase mediated conjugation of peptides
US6974187B2 (en) * 2004-01-28 2005-12-13 Tachi-S Co., Ltd. Vehicle seat structure
US20070123453A1 (en) * 2004-03-29 2007-05-31 Heiman Mark L Uses of melanocortin-4 receptor (mc4r) agonist peptides administered by continuous infusion
WO2006041769A2 (en) * 2004-10-05 2006-04-20 Merck & Co., Inc. Methods for the treatment of substance abuse and addiction
WO2006060873A1 (en) * 2004-12-09 2006-06-15 Prince Henry's Institute Of Medical Research Method for restoring reproductive function
WO2006073771A2 (en) * 2005-01-05 2006-07-13 Eli Lilly And Company Polyethylene glycol linked mc4r or mc3r agonist peptides
WO2006073772A1 (en) * 2005-01-05 2006-07-13 Eli Lilly And Company Polyethylene glycol linked mc4r or mc3r agonist peptides
US20070021433A1 (en) 2005-06-03 2007-01-25 Jian-Qiang Fan Pharmacological chaperones for treating obesity
US7754691B1 (en) 2005-07-07 2010-07-13 Palatin Technologies, Inc. Linear melanocortin receptor-specific peptides for cachexia
WO2007008684A2 (en) 2005-07-08 2007-01-18 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Ligands of melanocortin receptors
KR101232201B1 (ko) 2005-07-08 2013-02-12 입센 파마 에스.에이.에스 멜라노코르틴 수용체 리간드
WO2007077112A1 (en) * 2005-12-30 2007-07-12 F. Hoffmann-La Roche Ag Methods for the synthesis of arginine-containing peptides
AU2007255366B2 (en) 2006-06-09 2013-07-18 Synact Pharma Aps Phenyl pyrrole aminoguanidine derivatives
US7981998B2 (en) 2006-12-14 2011-07-19 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
CN101636407B (zh) 2006-12-14 2015-08-26 爱勒让治疗公司 双巯基大环化系统
JP5649825B2 (ja) 2007-01-31 2015-01-07 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 安定化させたｐ５３ペプチドおよびその使用法
ES2649941T3 (es) 2007-02-23 2018-01-16 Aileron Therapeutics, Inc. Aminoácidos sustituidos para preparar péptidos macrocíclicos unidos a triazol
ES2430067T3 (es) 2007-03-28 2013-11-18 President And Fellows Of Harvard College Polipéptidos cosidos
CA2689016C (en) 2007-05-25 2014-08-12 Ipsen Pharma S.A.S. Melanocortin receptor ligands modified with hydantoin
US20090275519A1 (en) * 2008-02-08 2009-11-05 Aileron Therapeutics, Inc. Therapeutic peptidomimetic macrocycles
EP2310407A4 (en) * 2008-04-08 2011-09-14 Aileron Therapeutics Inc BIOLOGIC EFFECTIVE PEPTIDOMIMETIC MACROCYCLES
US20110144303A1 (en) * 2008-04-08 2011-06-16 Aileron Therapeutics, Inc. Biologically Active Peptidomimetic Macrocycles
AR072072A1 (es) * 2008-06-09 2010-08-04 Palatin Technologies Inc Peptidos especificos del receptor de melanocortina para el tratamiento de la obesidad / 669
WO2009152079A1 (en) 2008-06-09 2009-12-17 Palatin Technologies, Inc. Melanocortin receptor-specific peptides for treatment of sexual dysfunction
WO2010011313A2 (en) * 2008-07-23 2010-01-28 President And Fellows Of Harvard College Ligation of stapled polypeptides
CN104961795A (zh) 2008-09-22 2015-10-07 爱勒让治疗公司 用于制备纯化的多肽组合物的方法
JP2012515172A (ja) 2009-01-14 2012-07-05 エルロン・セラピューティクス・インコーポレイテッド ペプチド模倣大環状分子
KR101726893B1 (ko) 2009-06-08 2017-04-13 팔라틴 테크놀로지스 인코포레이티드 멜라노코르틴 수용체-특이적 펩티드
WO2010144341A2 (en) 2009-06-08 2010-12-16 Palatin Technologies, Inc. Lactam-bridged melanocortin receptor-specific peptides
UY32690A (es) 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
WO2011008260A2 (en) 2009-07-13 2011-01-20 President And Fellows Of Harvard College Bifunctional stapled polypeptides and uses thereof
JP2013505300A (ja) 2009-09-22 2013-02-14 エルロン・セラピューティクス・インコーポレイテッド ペプチド模倣大環状分子
WO2011060355A1 (en) * 2009-11-16 2011-05-19 Ipsen Pharma S.A.S Process for the synthesis of ac-arg-cyclo(cys-d-ala-his-d-phe-arg-trp-cys)-nh2
EP2504351A4 (en) 2009-11-23 2013-10-30 Palatin Technologies Inc MELANOCORTIN-1 RECEPTOR-SPECIFIC LINEAR PEPTIDE
MX2012005862A (es) 2009-11-23 2012-09-07 Palatin Technologies Inc Peptidos ciclicos especificos del receptor de melanocortina-1.
CN101824415A (zh) * 2010-03-31 2010-09-08 华东师范大学 黑素皮质1型受体基因的snp及其应用
KR20170058446A (ko) 2010-08-13 2017-05-26 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
WO2012040459A2 (en) 2010-09-22 2012-03-29 President And Fellows Of Harvard College Beta-catenin targeting peptides and uses thereof
US9018395B2 (en) 2011-01-27 2015-04-28 Université de Montréal Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators
US9487562B2 (en) 2011-06-17 2016-11-08 President And Fellows Of Harvard College Stabilized polypeptides as regulators of RAB GTPase function
RU2639523C2 (ru) 2011-10-18 2017-12-21 Эйлерон Терапьютикс, Инк. Пептидомиметические макроциклы и их применение
CA2864120A1 (en) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
CA2862038C (en) 2012-02-15 2021-05-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
DK2920197T3 (da) 2012-09-26 2021-05-31 Harvard College Prolinlåste sammenhæftede peptider og anvendelser deraf
JP6526563B2 (ja) 2012-11-01 2019-06-05 エイルロン セラピューティクス，インコーポレイテッド 二置換アミノ酸ならびにその調製および使用の方法
SG10201700952XA (en) 2013-03-13 2017-04-27 Harvard College Stapled and stitched polypeptides and uses thereof
US10227390B2 (en) 2013-06-14 2019-03-12 President And Fellows Of Harvard College Stabilized polypeptide insulin receptor modulators
US10533039B2 (en) 2014-05-21 2020-01-14 President And Fellows Of Harvard College Ras inhibitory peptides and uses thereof
MX2017003797A (es) 2014-09-24 2017-06-15 Aileron Therapeutics Inc Macrociclos peptidomimeticos y usos de los mismos.
CA2961029A1 (en) 2014-09-24 2016-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and formulations thereof
CN107614003A (zh) 2015-03-20 2018-01-19 艾瑞朗医疗公司 拟肽大环化合物及其用途
WO2017004548A1 (en) 2015-07-01 2017-01-05 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US10023613B2 (en) 2015-09-10 2018-07-17 Aileron Therapeutics, Inc. Peptidomimetic macrocycles as modulators of MCL-1
CN110681362B (zh) * 2019-09-26 2020-09-11 浙江大学 以羧基和吲哚基为功能基团的混合模式层析介质
US11932628B2 (en) 2021-01-04 2024-03-19 Regents Of The University Of Minnesota Selective small molecule peptidomimetic melanocortin ligands

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5462927A (en) 1985-04-30 1995-10-31 The Administrators Of The Tulane Educational Fund Peptides aiding nerve regeneration
DE3851002T2 (de) 1987-05-22 1995-02-02 University Patents, Inc., Westport, Conn. Lineare und zyklische Analoge von alpha-MSH-Fragmenten mit ausserordentlicher Wirkung.
JP2795449B2 (ja) 1987-09-24 1998-09-10 ジ・アドミニストレーターズ・オブ・ザ・ツーレイン・エデュケイショナル・ファンド 治療用ペプチド
ZA908610B (en) 1989-11-03 1991-08-28 Univ Tulane Peptides aiding nerve regeneration
CA2061246A1 (en) 1991-02-15 1992-08-16 Mitsuhiro Wakimasu Peptides having antagonistic activities to endothelin receptors, production and use thereof
ATE155486T1 (de) 1991-08-13 1997-08-15 Takeda Chemical Industries Ltd Zyklische peptide und ihre verwendung
ES2133295T3 (es) 1991-11-19 1999-09-16 Takeda Chemical Industries Ltd Peptidos ciclicos y su uso.
EP0547317A1 (en) 1991-12-19 1993-06-23 Takeda Chemical Industries, Ltd. Endothelin antagonists
DE9203901U1 (de) 1992-03-24 1992-07-16 Croon & Lucke Maschinenfabrik Gmbh, 7947 Mengen Gestell zum Lagern von flächigen Werkstücken
DE69330868T2 (de) 1992-07-27 2002-04-25 Biomeasure Inc Antagonisten des neuromedin b rezeptors
US5569741A (en) 1992-07-27 1996-10-29 Biomeasure, Inc. Cyclic octapeptide neuromedin B receptor antagonists
AU673731B2 (en) 1993-06-03 1996-11-21 Banyu Pharmaceutical Co., Ltd. Novel endothelin antagonistic peptide
EP0714909A1 (en) 1994-12-01 1996-06-05 Takeda Chemical Industries, Ltd. Composition for prophylaxis or treatment of pulmonary circulatory diseases
US5731408A (en) * 1995-04-10 1998-03-24 Arizona Board Of Regents On Behalf Of The University Of Arizona Peptides having potent antagonist and agonist bioactivities at melanocortin receptors
US6054556A (en) * 1995-04-10 2000-04-25 The Arizona Board Of Regents On Behalf Of The University Of Arizona Melanocortin receptor antagonists and agonists
CA2215737A1 (en) 1995-04-28 1996-10-31 Koichi Kato Lh-rh receptor antagonists
US5817750A (en) 1995-08-28 1998-10-06 La Jolla Cancer Research Foundation Structural mimics of RGD-binding sites
US6362164B1 (en) 1996-06-11 2002-03-26 Novartis Ag Combination of a somatostatin analogue and a rapamycin
CA2258487A1 (en) 1996-06-25 1997-12-31 Nisshin Flour Milling Co., Ltd. Cyclic depsipeptides and drugs containing the same as the active ingredient
EP0815870A3 (en) 1996-06-27 2000-05-03 Takeda Chemical Industries, Ltd. Composition for prohylaxis or treatment of cerebral infarction
US5770380A (en) 1996-09-13 1998-06-23 University Of Pittsburgh Synthetic antibody mimics--multiple peptide loops attached to a molecular scaffold
IT1288388B1 (it) 1996-11-19 1998-09-22 Angeletti P Ist Richerche Bio Uso di sostanze che attivano il recettore del cntf ( fattore neurotrofico ciliare) per la preparazione di farmaci per la terapia
CA2275442A1 (en) 1996-12-17 1998-06-25 Quadrant Holdings Cambridge Limited Melanocortin derivatives for specific binding of melanocortin receptor 3, 4 or 5
SE9700620D0 (sv) * 1997-02-21 1997-02-21 Wapharm Ab Cykliska peptider med selektivitet för MSH-receptor subtyper
GB9827500D0 (en) 1998-12-14 1999-02-10 Wapharm Ab Compounds for control of eating, growth and body weight

Also Published As

Publication number Publication date
DE60038734T2 (de) 2009-07-02
EP1165613B1 (en) 2008-04-30
AR023201A1 (es) 2002-09-04
KR20050009722A (ko) 2005-01-25
KR100519201B1 (ko) 2005-10-06
CN1345335A (zh) 2002-04-17
HK1044954B (zh) 2008-11-21
TWI250990B (en) 2006-03-11
US6951916B2 (en) 2005-10-04
CZ20013407A3 (cs) 2002-02-13
CO5170531A1 (es) 2002-06-27
PE20001641A1 (es) 2001-02-07
NZ514141A (en) 2004-01-30
SA00210192B1 (ar) 2006-06-04
ZA200107411B (en) 2002-05-29
NO20014568L (no) 2001-11-29
AU4017900A (en) 2000-10-16
AU763510B2 (en) 2003-07-24
ATE393783T1 (de) 2008-05-15
ES2304345T3 (es) 2008-10-16
NO20014568D0 (no) 2001-09-20
MXPA01009881A (es) 2002-05-06
CA2368431C (en) 2006-01-24
US6613874B1 (en) 2003-09-02
RU2213098C2 (ru) 2003-09-27
SK13082001A3 (sk) 2002-03-05
KR100558131B1 (ko) 2006-03-10
BR0009497A (pt) 2002-01-15
DK1165613T3 (da) 2008-08-25
WO2000058361A1 (en) 2000-10-05
DE60038734D1 (de) 2008-06-12
TR200102765T2 (tr) 2002-05-21
HK1044954A1 (en) 2002-11-08
MA25403A1 (fr) 2002-04-01
PL350095A1 (en) 2002-11-04
CA2368431A1 (en) 2000-10-05
HUP0202203A3 (en) 2003-09-29
IL145406A0 (en) 2002-06-30
MY126585A (en) 2006-10-31
EP1165613A1 (en) 2002-01-02
JP2002542159A (ja) 2002-12-10
CN1249086C (zh) 2006-04-05
KR20020008143A (ko) 2002-01-29
US20040023859A1 (en) 2004-02-05
PT1165613E (pt) 2008-07-29
HUP0202203A2 (en) 2002-10-28

Similar Documents

Publication Publication Date Title
ID30262A (id) Ligan reseptor melanokortin
DE60020617D1 (de) Zementierkopf
DE69932238D1 (de) Epoxidierungsverfahren
NO20016115D0 (no) Substituerte heterocykelkondenserte gamma-karboliner
PT1224180E (pt) Azois substituidos
PT1210113E (pt) Composicoes de vacinas de combinacao
PT1218009E (pt) Grandulos de quetiapina
NO20013997D0 (no) Reseptoranalyse
PT1218096E (pt) Microcapsulas de libertacao variavel
PT1163256E (pt) Hemi-hidrato de 16-alfa-bromoepiandrosterona
DE50015795D1 (de) Sektionaltor
NO20016151D0 (no) Fremstilling av substituerte piperidin-4-oner
PT1235566E (pt) Formulacao injectavel de valnemulina
ID28032A (id) TRISIKLIK PIPERIDIN-Δ3-SEBAGAI ANTAGONIS-α2
DE60026931D1 (de) Ausrichtung von Ausdrucken
NO20021295L (no) Nikotinsyreacetylcholin-reseptor
DK1194426T3 (da) Benzofuranderivater
PT1178984E (pt) Derivados de 1-trifluorometil-4-hidroxi-7-piperidinilamimometilcromano
NO20022927L (no) Substituerte pyrrazoler
PT1175417E (pt) Compostos substituidos de benzolactamas
DE50006201D1 (de) Bohle
ID30381A (id) Penggunaan arilalkanoilpiridazina
DE50005694D1 (de) Zentrifuge
PT1232141E (pt) Eteres de o-desmetil-venlafaxina
DK1030319T3 (da) Ringkerne